327 related articles for article (PubMed ID: 36106637)
1. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.
Kaelin WG
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 36106637
[TBL] [Abstract][Full Text] [Related]
2. THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.
Kaelin WG
Trans Am Clin Climatol Assoc; 2022; 132():170-181. PubMed ID: 36196173
[TBL] [Abstract][Full Text] [Related]
3. The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
Kaelin WG
Trans Am Clin Climatol Assoc; 2017; 128():298-307. PubMed ID: 28790514
[TBL] [Abstract][Full Text] [Related]
4. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH; Kaelin WG
Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
6. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
8. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
Frost J; Rocha S; Ciulli A
J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
[TBL] [Abstract][Full Text] [Related]
9. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
10. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
Haase VH
Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
12. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
13. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
Chakraborty AA
Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
[TBL] [Abstract][Full Text] [Related]
14. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
15. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
17. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
Kaelin WG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
[TBL] [Abstract][Full Text] [Related]
18. Alterations in VHL as potential biomarkers in renal-cell carcinoma.
Gossage L; Eisen T
Nat Rev Clin Oncol; 2010 May; 7(5):277-88. PubMed ID: 20368728
[TBL] [Abstract][Full Text] [Related]
19. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
20. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
